Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06325605
Other study ID # GRYY-LL-KJ2022-064
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2022
Est. completion date October 31, 2022

Study information

Verified date March 2024
Source Tangshan Worker's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A total of 100 patients with adolescent depression who were admitted to our hospital between March 2022 and October 2022 were selected. On the basis of double blinding, these patients were randomly divided into the observation group(n=50) and the control group(n=50) using a random number table. 5S management method was used in the whole process of treatment to improve the hospital environment, increase the work efficiency and reduce the occurrence of cross infection through the effective implementation of the five steps of sort(Seiri), set in order(Seiton), shine (Seiso), standardize(Seiketsu) and sustain(Shitsuke).


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date October 31, 2022
Est. primary completion date October 31, 2022
Accepts healthy volunteers No
Gender All
Age group 13 Years to 18 Years
Eligibility Inclusion Criteria: - aged 13-18 years old; - met the diagnostic criteria for depression in the International Classification of Disease-10 (ICD-10); - with a total score of the Hamilton Rating Scale for Depression (HAMD-24) =20 in the initial assessment; - who were right-handed Exclusion Criteria: - with a definite diagnosis of other mental disorders in the past; - with a past or current history of manic episodes; - with a past or current history of severe physical diseases; - who used antidepressants, mood stabilizers, steroids, anti-inflammatory drugs, antibiotics, and immunomodulators in the past 1 month; - who used lactic acid bacteria products for =7 days in the past 1 month; - with a history of alcohol or psychoactive substance abuse within the last 3 months; - with contraindications for rTMS, including but not limited to intracranial metal foreign bodies, cardiac pacemakers, and ear hearing aids; - complicated with organic brain diseases, epileptic diseases, and severe physical diseases

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bifidobacterium
3 capsules, 3 times a day, for 8 consecutive weeks
Device:
High-frequency rTMS
In the rTMS treatment, the transcranial magnetic stimulation device with an "8"-shaped coil with a diameter of 70mm was placed on the dorsolateral area of the left prefrontal lobe of the patient. The motor threshold was set to 90%. A 10-Hz pulse sequence was applied for 4 secs followed by a 20 secs interval. 10 pulses per train were used, and the total stimulation time was 30mins per day, 4 times a week, for 8 consecutive weeks.
Drug:
Escitalopram Oxalate
Oral escitalopram oxalate. The initial dose was 5mg/d, for 7 consecutive days. The dose was increased to 10 mg/d according to the tolerance of the patients for another 7 consecutive days, and then to 20 mg/d according to the patient's condition and tolerance for 8 weeks

Locations

Country Name City State
China Tangshan Workers' Hospital Tangshan Hebei

Sponsors (1)

Lead Sponsor Collaborator
Zhen-Hong Hu

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary HAMD-24 scores Final scores were interpreted as no depression (<20), mild or moderate depression (=20), and severe depression (=35) 4 times a week, for 8 consecutive weeks
Primary TNF-a About 5ml of fasting venous blood was collected in the morning, centrifuged at 3000rpm for 10mins, and the upper serum was collected. The levels of serum tumor necrosis factor-a(TNF-a), interleukin-1ß(IL-1ß), IL-6, dopamine(DA), 5-hydroxytryptamine(5-HT) and cortisol(COR) were measured by ELISA using an automatic biochemical analyzer(Dxc800, Beckman, USA). The relative expression levels of serum miR-16 and miR-195 were determined by PCR. All measurements were strictly conducted by laboratory specialists following the instructions of the instruments and kits. 7 consecutive days
Primary IL-1ß About 5ml of fasting venous blood was collected in the morning, centrifuged at 3000rpm for 10mins, and the upper serum was collected. The levels of serum tumor necrosis factor-a(TNF-a), interleukin-1ß(IL-1ß), IL-6, dopamine(DA), 5-hydroxytryptamine(5-HT) and cortisol(COR) were measured by ELISA using an automatic biochemical analyzer(Dxc800, Beckman, USA). The relative expression levels of serum miR-16 and miR-195 were determined by PCR. All measurements were strictly conducted by laboratory specialists following the instructions of the instruments and kits. 7 consecutive days
Primary IL-6 About 5ml of fasting venous blood was collected in the morning, centrifuged at 3000rpm for 10mins, and the upper serum was collected. The levels of serum tumor necrosis factor-a(TNF-a), interleukin-1ß(IL-1ß), IL-6, dopamine(DA), 5-hydroxytryptamine(5-HT) and cortisol(COR) were measured by ELISA using an automatic biochemical analyzer(Dxc800, Beckman, USA). The relative expression levels of serum miR-16 and miR-195 were determined by PCR. All measurements were strictly conducted by laboratory specialists following the instructions of the instruments and kits. 7 consecutive days
Primary DA About 5ml of fasting venous blood was collected in the morning, centrifuged at 3000rpm for 10mins, and the upper serum was collected. The levels of serum tumor necrosis factor-a(TNF-a), interleukin-1ß(IL-1ß), IL-6, dopamine(DA), 5-hydroxytryptamine(5-HT) and cortisol(COR) were measured by ELISA using an automatic biochemical analyzer(Dxc800, Beckman, USA). The relative expression levels of serum miR-16 and miR-195 were determined by PCR. All measurements were strictly conducted by laboratory specialists following the instructions of the instruments and kits. 7 consecutive days
Primary 5-HT About 5ml of fasting venous blood was collected in the morning, centrifuged at 3000rpm for 10mins, and the upper serum was collected. The levels of serum tumor necrosis factor-a(TNF-a), interleukin-1ß(IL-1ß), IL-6, dopamine(DA), 5-hydroxytryptamine(5-HT) and cortisol(COR) were measured by ELISA using an automatic biochemical analyzer(Dxc800, Beckman, USA). The relative expression levels of serum miR-16 and miR-195 were determined by PCR. All measurements were strictly conducted by laboratory specialists following the instructions of the instruments and kits. 7 consecutive days
Primary COR About 5ml of fasting venous blood was collected in the morning, centrifuged at 3000rpm for 10mins, and the upper serum was collected. The levels of serum tumor necrosis factor-a(TNF-a), interleukin-1ß(IL-1ß), IL-6, dopamine(DA), 5-hydroxytryptamine(5-HT) and cortisol(COR) were measured by ELISA using an automatic biochemical analyzer(Dxc800, Beckman, USA). The relative expression levels of serum miR-16 and miR-195 were determined by PCR. All measurements were strictly conducted by laboratory specialists following the instructions of the instruments and kits. 7 consecutive days
Primary Serum miR-16 About 5ml of fasting venous blood was collected in the morning, centrifuged at 3000rpm for 10mins, and the upper serum was collected. The levels of serum tumor necrosis factor-a(TNF-a), interleukin-1ß(IL-1ß), IL-6, dopamine(DA), 5-hydroxytryptamine(5-HT) and cortisol(COR) were measured by ELISA using an automatic biochemical analyzer(Dxc800, Beckman, USA). The relative expression levels of serum miR-16 and miR-195 were determined by PCR. All measurements were strictly conducted by laboratory specialists following the instructions of the instruments and kits. 7 consecutive days
Primary Serum miR-195 About 5ml of fasting venous blood was collected in the morning, centrifuged at 3000rpm for 10mins, and the upper serum was collected. The levels of serum tumor necrosis factor-a(TNF-a), interleukin-1ß(IL-1ß), IL-6, dopamine(DA), 5-hydroxytryptamine(5-HT) and cortisol(COR) were measured by ELISA using an automatic biochemical analyzer(Dxc800, Beckman, USA). The relative expression levels of serum miR-16 and miR-195 were determined by PCR. All measurements were strictly conducted by laboratory specialists following the instructions of the instruments and kits. 7 consecutive days
See also
  Status Clinical Trial Phase
Completed NCT00399776 - Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy N/A
Completed NCT04603053 - Determining Effectiveness of an mHealth Intervention to Provide Adolescent CBT N/A
Completed NCT01802437 - An Adaptive Treatment Strategy for Adolescent Depression Phase 1/Phase 2
Completed NCT02017535 - An Adaptive Treatment Strategy for Adolescent Depression-Continuation Phase 1/Phase 2
Completed NCT03154008 - Predictors of Response to Treatment for Depression N/A
Recruiting NCT04613453 - Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine Phase 2
Terminated NCT00284791 - Lamotrigine in Treatment Resistant Depression in Adolescents N/A
Completed NCT00312897 - Omega-3 Fatty Acids in Adolescent Depression Phase 2
Recruiting NCT01857518 - Depression in Adolescents. A Cerebral Structural, Diffusion, and Functional Magnetic Resonance Imaging Study N/A
Recruiting NCT06072677 - Adolescent Mood During Puberty and Testosterone N/A
Recruiting NCT01170520 - Repetitive Transcranial Stimulation (rTMS) for Resistant Depression in Adolescents Phase 1/Phase 2